Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Russell 2000 ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while iShares Russell 2000 ETF trades at $302.09. Which is the better fit depends on your goals.
| ADPT | IWM | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $301.69 |
52-Week Low | $12.30 | $225.45 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
IWM trades at $302.3, up 0.77% with a bullish technical outlook supported by moving averages, though RSI suggests mild overbought conditions. The ETF, tracking the Russell 2000 small-cap index, benefits from institutional favor due to deep liquidity and options markets. Small caps are outperforming large caps year-to-date, with the Russell 2000 up approximately 20% as of July 17, 2026 (24/7 Wall Street).
Outlook remains positive for small-cap exposure amid broadening market rally, but risks include higher volatility and economic sensitivity. Investors gain diversified small-cap access, yet should monitor valuation gaps versus alternatives and interest rate impacts highlighted by Goldman Sachs on July 7, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
